Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrike Heider

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|July 5, 2007
Molecular and clinical aspects of proteasome inhibition in the treatment of cancerIvana Zavrski, Christian Jakob, Martin Kaiser, et al.
Biochemical and Biophysical Research Communications|October 12, 2005
Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone diseaseUlrike Heider, Lorenz C Hofbauer, Ivana Zavrski, et al.
British Journal of Haematology|June 27, 2007
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPKMonica Hecht, Ulrike Heider, Martin Kaiser, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2010
Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomibUlrike Heider, Jessica Rademacher, Martin Kaiser, et al.
British Journal of Haematology|October 3, 2002
Serum levels of VEGF do not correlate with the severity of multiple myelomaChristian Jakob, Ivana Zavrski, Ulrike Heider, et al.
European Journal of Haematology|January 15, 2013
The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signallingMartin F Kaiser, Ulrike Heider, Maren Mieth, et al.
Biochemical and Biophysical Research Communications|June 7, 2005
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast functionIvana Zavrski, Holger Krebbel, Britt Wildemann, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2006
Bone markers in multiple myelomaUlrike Heider, Claudia Fleissner, Ivana Zavrski, et al.
Experimental Cell Research|May 5, 2009
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myelomaIvana von Metzler, Ulrike Heider, Maren Mieth, et al.
Blood|June 18, 2002
Immunocytochemistry reveals RANKL expression of myeloma cellsOrhan Sezer, Ulrike Heider, Christian Jakob, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|July 5, 2007
Molecular and clinical aspects of proteasome inhibition in the treatment of cancerIvana Zavrski, Christian Jakob, Martin Kaiser, et al.
Biochemical and Biophysical Research Communications|October 12, 2005
Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone diseaseUlrike Heider, Lorenz C Hofbauer, Ivana Zavrski, et al.
British Journal of Haematology|June 27, 2007
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPKMonica Hecht, Ulrike Heider, Martin Kaiser, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2010
Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomibUlrike Heider, Jessica Rademacher, Martin Kaiser, et al.
British Journal of Haematology|October 3, 2002
Serum levels of VEGF do not correlate with the severity of multiple myelomaChristian Jakob, Ivana Zavrski, Ulrike Heider, et al.
European Journal of Haematology|January 15, 2013
The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signallingMartin F Kaiser, Ulrike Heider, Maren Mieth, et al.
Biochemical and Biophysical Research Communications|June 7, 2005
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast functionIvana Zavrski, Holger Krebbel, Britt Wildemann, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2006
Bone markers in multiple myelomaUlrike Heider, Claudia Fleissner, Ivana Zavrski, et al.
Experimental Cell Research|May 5, 2009
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myelomaIvana von Metzler, Ulrike Heider, Maren Mieth, et al.
Blood|June 18, 2002
Immunocytochemistry reveals RANKL expression of myeloma cellsOrhan Sezer, Ulrike Heider, Christian Jakob, et al.
Pageof 5